Diadem is actively building new partnerships both in drug development and diagnosis of Alzheimer’s disease with industrial and academic partners.


Diadem works in a close and continuous collaboration with the University of Brescia (Italy) sustaining PostDoc position and Alzheimer’s disease projects research from the Molecular and Translational Medicine Department, Pharmacology Group.




Diadem is collaborating with the Australian Imaging, Biomarker and Lifestyle Study of Ageing (AIBL). AIBL is one of the largest, well-characterised, longitudinal cohorts of healthy ageing and cognitive decline in the world. AIBL focuses on the development of dementia and the identification of factors influencing its timing and occurrence. Innovative biomarker and imaging technologies are utilised to study the natural history of Alzheimer’s disease.




Diadem developed its diagnostic tools in collaboration with Future Diagnostics B.V. and HyCult Biotech.